Rectifying function, restoring hope

Jason Rhodes is a Partner at Atlas Venture and focuses on creating and building novel therapeutics companies. Jason is the Executive Chair of the Board of Rectify. Jason was the founding CEO of Generation Bio and Dyne Therapeutics. He is also on the boards of Replimune, Accent Therapeutics, and Be Biopharma. He was the chair and founding CEO of Disarm Therapeutics, acquired by Eli Lilly. Previously, Jason held leadership positions at Epizyme, where he was President and built the company from early-stage research into the clinic and through a successful IPO, and at Alnylam Pharmaceuticals, where he led business development. Jason was also a founder and partner with Fidelity Biosciences (now F-Prime Capital), the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including FoldRx, acquired by Pfizer. He is a member of the advisory board of the Harvard Institute for RNA Medicine, the Blavatnik Fund at Yale University, and the Berklee College of Music Presidential Advisory Council. Jason received his B.A. from Yale University and his M.B.A. from the Wharton School of the University of Pennsylvania.

Rajesh (Raj) Devraj, Ph.D., is President and Chief Executive Officer of Rectify and a Venture Partner at Atlas Venture. Throughout his career, he has been focused on creating and building groundbreaking biotech companies. Prior to Rectify, Raj co-founded Disarm Therapeutics with Atlas and served as its Chief Scientific Officer prior to its acquisition. Before Disarm, he served as Chief Scientific Officer of Atlas-founded Padlock Therapeutics. Prior to his tenure at Atlas, Raj served in senior executive roles at Euclises & Deciphera Pharmaceuticals and at Jubilant Life Sciences. In addition, Raj spent 14 years in positions of increasing responsibility with Pfizer Global R&D and the legacy Pharmacia and Searle companies. Raj also serves on the boards of directors for several biotech companies. Over a 25-year career in large pharma and biotech, Raj has led discovery, early clinical development and strategic planning teams that have advanced multiple candidates into clinical trials for refractory cancers, autoimmune diseases, IPF, diabetic nephropathy, COPD, and pain. Raj received his B.S. in Pharmacy from University of Mumbai, and Ph.D. in Medicinal Chemistry from Duquesne University.

Marco Boorsma, Ph.D., is a General Partner at Forbion. He has a background in molecular biology and biotechnology and brings operational and business development experience from both small and large businesses. Before joining Forbion, he was Business Development Director and Project Manager at DSM Pharmaceutical Products and a Scientist at Cytos Biotechnology in Switzerland. Marco also serves on the board of directors of Escalier Biosciences, NorthSea Therapeutics, Milestone Pharmaceuticals, RSPR Pharma, Prexton Therapeutics, and Engene, and is an observer to the board of directors of Exosome Diagnostics and Oxyrane. Previously, he served on the board of directors of Dezima Pharma, which was sold to Amgen, and on the board of directors of Akarna Therapeutics, which was sold to Allergan. After obtaining a master’s degree in Molecular Biology from the University of Groningen, he received his Ph.D. in Biotechnology from the ETH Institute for Technology in Zürich, and completed part of his research at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge, UK.

Jonathan Moore, Ph.D., is Founder and Chief Scientific Officer of Rectify. Prior to starting Rectify, Jon was a Founding Scientist at Vertex Pharmaceuticals, where he spent over 27 years as a Structural Biologist, leading early discovery efforts across multiple disease areas, including anti-infectives, oncology, pain and cystic fibrosis. During his tenure at Vertex, Jon led a cross-site basic research team, which was focused on understanding the molecular mechanisms of action of next-generation cystic fibrosis small molecule therapeutics. From 2018-2021, Jon was a Visiting Scientist and Principal Investigator in the Department of Biology at MIT, where his research focused on the structural and mechanistic basis of ABC transporter dysfunction in rare disease. Jon is considered a thought leader in Structural Biology and Drug Discovery, with an extensive publication record in peer-reviewed journals and invited lectures at major scientific symposia. Jon obtained his B.A. and Ph.D. in Biophysics from the University of Pennsylvania and postdoctoral training in high-resolution NMR at the Scripps Research Institute and at the ETH-Zürich in the lab of Nobel Laureate Kurt Wüthrich, where he was a Fogarty Fellow.

Otello Stampacchia, Ph.D., founded Omega Funds and leads the firm’s investor relations and strategic initiatives. He is a member of the firm’s investment committee and is also heavily involved in a number of Omega’s therapeutic areas of interest, particularly in oncology, rare diseases and inflammatory disorders. Previously, Otello was in charge of life sciences direct investments and diligence for healthcare venture fund of fund investments at AlpInvest Partners, one of the largest private equity asset managers worldwide. Before AlpInvest, he was the Portfolio Manager of the Lombard Odier Immunology Fund, a $3 billion listed investment vehicle in Geneva, Switzerland, investing in public and private healthcare companies worldwide. Previously, Otello was a member of the HealthCare corporate finance and M&A team at Goldman Sachs (London and New York offices). Before Goldman, he helped co-found the healthcare investment activities at Index Securities (now Index Ventures). Otello has a Ph.D. in Molecular Biology from the University of Geneva, holds a European Doctorate in Biotechnology from the EU, and obtained an MSc in Genetics from the University of Pavia.

David Steinberg is a General Partner at Longwood Fund. Previously, David was co-founder and Chief Innovation Officer at PureTech Health, where he focused on biotech venture creation and investing. David has served as founding CEO of multiple biotech companies, including Vor Biopharma, Pyxis Oncology, Be Biopharma, Vedanta Biosciences, Endra Life Sciences Inc., and Entrega Biosciences, and co-founded ResTORbio. Prior to that, David worked in biopharma strategy consulting at Boston Consulting Group and Vertex Partners, and in R&D at P&G Pharmaceuticals. He received his M.B.A. from the University of Chicago Booth School of Business and holds a B.A. in Biology from Cornell University.

Jodie Morrison is Venture Partner at Atlas Venture and an accomplished executive and board member who most recently served as CEO of Cadent Therapeutics, which Atlas formed and which was acquired by Novartis in 2021. Prior to Cadent, Jodie served as interim CEO at Keryx Biopharmaceuticals, Inc. where she led the successful merger with Akebia Therapeutics, and as acting COO at Syntimmune which was acquired by Alexion. Before that, she served as President and CEO of Tokai Pharmaceuticals, Inc. where she led the 2014 IPO and 2016 merger, and held other senior positions including Chief Operating Officer and Vice President, Head of Clinical and Program Operations. Earlier in her career, Jodie held roles in clinical operations and medical affairs at Dyax Corporation, Curis, Inc., and Diacrin, Inc. She serves on the boards of several biotech companies. Jodie received her B.S. in Neuroscience from Mount Holyoke College.